Asahi Kasei Pharma Corporation Sustainability Profile
Asahi Kasei Pharma Corporation, a prominent player in the pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and North America. Founded in 1941, the company has established itself as a leader in innovative healthcare solutions, focusing on prescription pharmaceuticals, regenerative medicine, and diagnostic products. With a commitment to advancing medical science, Asahi Kasei Pharma is renowned for its unique offerings, including cutting-edge therapies for cardiovascular and metabolic diseases. The company’s dedication to research and development has led to significant milestones, positioning it as a trusted name in the global market. Asahi Kasei Pharma continues to enhance patient care through its high-quality products and a strong emphasis on sustainability and ethical practices.
DitchCarbon Score
How does Asahi Kasei Pharma Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Asahi Kasei Pharma Corporation's score of 70 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Asahi Kasei Pharma Corporation, headquartered in Japan (JP), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Asahi Kasei Corporation, which may influence its climate commitments and initiatives. While there are no documented reduction targets or specific climate pledges from Asahi Kasei Pharma Corporation, it is important to note that emissions data and performance metrics may be cascaded from its parent company, Asahi Kasei Corporation. This relationship suggests that any climate initiatives or targets may align with the broader corporate strategies of the parent organisation. Asahi Kasei Corporation has been active in addressing climate change, and it is advisable to refer to their emissions data and sustainability initiatives for a comprehensive understanding of the group's overall environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2000 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
How Carbon Intensive is Asahi Kasei Pharma Corporation's Industry?
How Carbon Intensive is Asahi Kasei Pharma Corporation's Location?
Asahi Kasei Pharma Corporation's Scope 3 Categories Breakdown
Asahi Kasei Pharma Corporation's Scope 3 emissions, which decreased by 0% last year and increased by approximately 113% since 2015, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 79% of total emissions under the GHG Protocol, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 41% of Scope 3 emissions.
Top Scope 3 Categories
Asahi Kasei Pharma Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Asahi Kasei Pharma Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.